RT Journal Article
SR Electronic
T1 Usefulness of serum anti-glycopeptidolipid core IgA antibody assay for the diagnosis of pulmonary infection of mycobacterium avium complex
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2599
VO 44
IS Suppl 58
A1 Sayaka Arakawa
A1 Akira Yokoyama
A1 Yuki Shinno
A1 Kota Itahashi
A1 Asae Kamiyama
A1 Masaki Kawakami
A1 Masaru Suzuki
A1 Yoshio Sakamoto
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2599.abstract
AB Background: The number of patients with mycobacterium avium complex(MAC)-pulmonary disease is increasing world-widely. As it is sometimes difficult to detect the organism in specimens obtained from respiratory tract, not a few patients remain suspicious MAC-pulmonary disease in spite of typical radiographycal findings on chest X-ray and CT. Serum IgA class antibody(Ab) raised against MAChas been developed for an alternative method to diagnose MAC infection, but it still needs to be validated.Purpose: We measured anti-GPL core Abs in patients who had been followed in the outpatient clinic of Kanto Central Hospital with diagnosis of definite or suspicious MAC-pulmonary disease and its usefulness was evaluated.Methods: Anti-GPL core IgA Abs were assayed by ELISA kits. The cut-off value was set at 0.5 U/ml. Serum levels were measured in 92 patients(definite 45, and suspicious 47; 82(89%) females, and aged from 32 to 87 years). Anti-MAC therapy was administered in 21(47%) out or 45 definite cases.Results: Serum Ab levels were elevated in 72(78%) of 92 patients; 42(93%) out of 45 definite cases, and 32(68%) out of 47 suspicious cases. The Ab levels were elevated in 19(91%) out of 21 patients who received anti-MAC therapy.Conclusion: Measurement of serum anti-GPL core IgA Abs seems useful for the diagnosis of MAC-pulmonary disease in patients in whom the detection of the organism was unsuccessful or difficult. It may also provide information for the decision making of administration of anti-MAC microbial therapy.